SCHEMBL7958191

SCHEMBL7958191

COc1ccc2c(c1)CCC(O)C2

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.58
DRD3 P35462 7/20 0.58
CYP26A1 O43174 1/20 0.56
CA1 P00915 4/20 0.55
CA2 P00918 4/20 0.55
ACHE P22303 4/20 0.55
CYP19A1 P11511 2/20 0.52
DRD4 P21917 2/20 0.51
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
DRD1 P21728 1/20 0.47
DRD5 P21918 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL629692 0.93 DRD2 (0.66) DRD2DRD3CYP26A1CA1CA2
SCHEMBL4001498 0.93 DRD2 (0.66) DRD2DRD3CYP26A1CA1CA2
SCHEMBL6403014 0.93 DRD2 (0.66) DRD2DRD3CYP26A1CA1CA2
SCHEMBL3961628 0.85 DRD2 (0.54) DRD2DRD3CYP26A1CA1CA2
SCHEMBL23343811 0.85 DRD2 (0.54) DRD2DRD3CYP26A1CA1CA2
SCHEMBL5713209 0.84 CYP1A2 (0.58) DRD2DRD3CYP26A1CA1CA2
SCHEMBL4000915 0.83 DRD2 (0.58) DRD2DRD3CA1CA2ACHE
SCHEMBL8765765 0.83 DRD2 (0.58) DRD2DRD3CA1CA2ACHE
SCHEMBL4000913 0.83 DRD2 (0.58) DRD2DRD3CA1CA2ACHE
SCHEMBL7948432 0.82 DRD2 (0.48) DRD2DRD3CYP26A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475262-B1 BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS BOEHRINGER INGELHEIM INT (DE) 2021-03-24 EP disclosed
US-10858342-B2 Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-12-08 US disclosed
US-20200109131-A1 BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-04-09 US disclosed
US-6265398-B1 INSECTICIDES, FUNGICIDES, ANTIFERTILITY AGENTS HOECHST SCHERING AGREVO GMBH (DE) 2001-07-24 US disclosed
EP-0898565-A1 SUBSTITUTED PYRIDINES/PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS PEST CONTROL AGENTS Hoechst Schering AgrEvo GmbH (DE) 1999-03-03 EP disclosed
WO-1997038979-A1 SUBSTITUTED PYRIDINES/PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS PEST CONTROL AGENTS HOECHST SCHERING AGREVO GMBH (DE) 1997-10-23 WO disclosed
US-3984464-A ANTIARRHYTHMIA AGENTS A. CHRISTIAENS SOCIETE ANONYME (BE) 1976-10-05 US disclosed
US-3943172-A ANTIARRHYTHMIA A. CHRISTIAENS, SOCIETE ANONYME (BE) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858342-B2 Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases REN, AGTR1, AGTR2 DRD2 3287/4885DRD3 2933/4885CYP26A1 840/4885
US-20200109131-A1 BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES REN, AGTR1, AGTR2 DRD2 3287/4885DRD3 2933/4885CYP26A1 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.